Cargando…

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis

OBJECTIVE: To explore the cost-effectiveness of degarelix acetate for injection (degarelix) compared to leuprorelin in prostate cancer (Pca) castration treatment from Chinese healthcare system perspective. METHODS: A Markov model, adapted from the one established in Finland was conducted for the cos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Jianzhou, Li, Caiyun, Zhang, Xuefang, Cheng, Luyan, Ding, Ruilin, Zhang, Lingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339785/ https://www.ncbi.nlm.nih.gov/pubmed/35923949 http://dx.doi.org/10.3389/fpubh.2022.942800

Ejemplares similares

The Consistency Between the Chinese Essential Medicines List and Treatment Guidelines—Taking Oncology Medicines as an Example
por: Cheng, Luyan, et al.
Publicado: (2022)

Evaluation of degarelix in the management of prostate cancer
por: Van Poppel, Hendrik
Publicado: (2010)

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021)

Degarelix and its therapeutic potential in the treatment of prostate cancer
por: Doehn, Christian, et al.
Publicado: (2009)

Interstitial pneumonitis secondary to leuprorelin acetate for prostate cancer
por: Tan, Hsern Ern, et al.
Publicado: (2016)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Patent foramen ovale closure vs. medical therapy alone after cryptogenic stroke in China: A cost-effectiveness analysis
por: Wei, Na, et al.
Publicado: (2022)

Cost-utility analysis of centrally inserted totally implanted access port (PORT) vs. peripherally inserted central catheter (PICC) in the oncology chemotherapy
por: Shao, Guoliang, et al.
Publicado: (2022)

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
por: Rick, Ferenc G, et al.
Publicado: (2013)

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer
por: Tokiwa, Suguru, et al.
Publicado: (2017)

Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer
por: Sankaran, Sindhu, et al.
Publicado: (2023)

Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008)

Clinical studies investigating the use of leuprorelin for prostate cancer in Asia
por: Chung, Byung Ha, et al.
Publicado: (2020)

Cost-Utility Analysis of the Integrated Care Models for the Management of Hypertension Patients: A Quasi-Experiment in Southwest Rural China
por: Ke, Xiatong, et al.
Publicado: (2021)

Cost-effectiveness analysis of vaccination against COVID-19 in China
por: Zhou, Huixuan, et al.
Publicado: (2023)

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
por: Sun, Yinghao, et al.
Publicado: (2020)

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
por: Li, Wei, et al.
Publicado: (2022)

The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis
por: Wang, Ruilin, et al.
Publicado: (2023)

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
por: Lazenby, Mark
Publicado: (2012)

Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
por: Ong, Shawn Y., et al.
Publicado: (2015)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China
por: Lin, Ying-tao, et al.
Publicado: (2022)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
por: Lou, Yake, et al.
Publicado: (2022)

An occupational health survey on health utility and occupational diseases in Chinese university staff to inform cost-utility analysis
por: Liu, Xiaoyan, et al.
Publicado: (2023)

Knowledge of cataracts and eye care utilization among adults aged 50 and above in rural Western China
por: Du, Kang, et al.
Publicado: (2022)

Health utility of children with acute lymphoblastic leukemia in China
por: Wang, Wei, et al.
Publicado: (2023)

Cost-Effectiveness of Posaconazole vs. First-Generation Triazoles for the Prevention of Invasive Fungal Infections Among High-Risk Patients With Hematological Malignancies in China
por: Shi, Changcheng, et al.
Publicado: (2022)

The Basic vs. Ability-to-Pay Approach: Evidence From China's Critical Illness Insurance on Whether Different Measurements of Catastrophic Health Expenditure Matter
por: Zhang, Ying, et al.
Publicado: (2021)

Metamizole Utilization and Expenditure During 6-Year Period: Serbia vs. Croatia
por: Miljkovic, Milijana, et al.
Publicado: (2018)

Why can’t children with autism integrate into society in China? Study based on the perspective of NGO classification
por: Li, Zhiwei, et al.
Publicado: (2023)

Accessibility of essential anticancer medicines for children in the Sichuan Province of China
por: Chen, Zhe, et al.
Publicado: (2022)

Characterizing Potentially Preventable Hospitalizations of High-Cost Patients in Rural China
por: Lu, Shan, et al.
Publicado: (2022)

Effects of Docetaxel plus Degarelix on Quality of Life and Vascular Endothelial Growth Factor in Patients with Prostate Cancer
por: Li, Weiping, et al.
Publicado: (2022)

Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
por: Zhang, Weina, et al.
Publicado: (2023)

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
por: Melloni, Chiara, et al.
Publicado: (2020)

Birth defects data from hospital-based birth defect surveillance in Guilin, China, 2018–2020
por: Yang, Xingdi, et al.
Publicado: (2022)

Improving occupational health for health workers in a pilot hospital by application of the HealthWISE international tool: An interview and observation study in China
por: Zhang, Min, et al.
Publicado: (2022)

Inequity in Health Services Utilization in Economically Underdeveloped Regions of Northeast China
por: Zhang, Xin, et al.
Publicado: (2022)

Potential barriers in implementing the rural toilet retrofitting project: A qualitative study in Jiaozuo, China
por: Wang, Yuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8in7t95tbsidjn6e05acv2or73